Routine Tasks, Serious Outcomes
In early October, a pharmaceutical intermediates plant in western India reported a gas release during a process step, injuring six workers, three of them with serious burns, and producing eye and skin irritation reports across the site. The unit was evacuated and investigators opened a case. Weeks earlier, a synthesis plant in northern France was carrying out maintenance on vessels that still held chemical solvents when a container failed and ignited, severely burning one worker; monitoring found airborne concentrations below action thresholds, so nearby streets were reopened rather than cleared. In September, a pharmaceutical chemical site in China ran an exercise built around a failure at an external pipe joint on a reactor, tracing how a low-toxicity organic waste stream would reach the plant's storm drainage and then a river, and practising source containment, drain sealing and downstream dam closure.
Read together, the three point to where pharma's chemical risk actually sits. Not in exotic synthesis routes, but in transfer lines, vessel openings, filter and centrifuge handling, and the maintenance window when a reactor has been drained but is not yet clean.
The Glove Has Two Jobs
Hand protection in an intermediates or active-ingredient plant carries a requirement most hazmat users never face. The glove has to keep corrosive, biologically active chemistry off the worker and keep the worker's particles, residues and skin flora out of the product. A glove that passes a permeation test but sheds particles, or a cleanroom glove that was never assessed against the chemistry on site, solves only half of that.
This is why EN ISO 374 conformance alone is the wrong question. A cleanroom classification sets a particulate ceiling; it says nothing about chemical breakthrough. For cytotoxic intermediates and hazardous drug classes, buyers increasingly ask for results under ASTM D6978, which challenges at least nine named drugs and places the breakthrough threshold at 0.01 µg/cm²/min, some hundred times tighter than the 1 µg/cm²/min limit used in EN 16523-1 testing. Suppliers holding only EN 374 data should be asked what that data means for the specific compounds on the line. Double-gloving, an outer glove a half size up, and a documented donning and doffing sequence normally sit alongside the material choice.
Boots, Washdown and the Blind Spot
Footwear in these plants is judged by the floor as much as by the chemistry. Reactor charging, centrifuge discharge and spill clean-up all put dilute acid, solvent and product slurry underfoot, and the washdown water has to be contained rather than pushed into yard drains, the same containment logic the Chinese exercise was built around. Boots need proven slip resistance on wet coated floors, a shaft height that suits washdown, and a construction that lets an operator change footwear at the clean-dirty boundary without carrying contamination inward.
One hazard deserves its own line in the risk assessment. Nitrogen inerting is standard in this sector, and asphyxiation has killed pharmaceutical workers at sites where chemical protection was never the weak point. No glove or boot addresses an oxygen-deficient atmosphere. Detection, permit control and rescue capability sit outside the PPE selection sheet, and a buyer who treats the glove specification as the whole safety case will miss it.